Emerging trends in organ-on-a-chip systems for drug screening.
10.1016/j.apsb.2023.02.006
- Author:
Yanping WANG
1
;
Yanfeng GAO
1
;
Yongchun PAN
1
;
Dongtao ZHOU
1
;
Yuta LIU
1
;
Yi YIN
1
;
Jingjing YANG
1
;
Yuzhen WANG
2
;
Yujun SONG
1
Author Information
1. College of Engineering and Applied Sciences, State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing 210023, China.
2. Key Laboratory of Flexible Electronics & Institute of Advanced Materials, Jiangsu National Synergistic Innovation Center for Advanced Materials, Nanjing Tech University, Nanjing 211816, China.
- Publication Type:Review
- Keywords:
Bioprinting;
Drug discovery;
Drug safety;
Human-on-a-chip;
In vitro models;
Microfluidics;
Microphysiological systems;
Toxicity assessment
- From:
Acta Pharmaceutica Sinica B
2023;13(6):2483-2509
- CountryChina
- Language:English
-
Abstract:
New drug discovery is under growing pressure to satisfy the demand from a wide range of domains, especially from the pharmaceutical industry and healthcare services. Assessment of drug efficacy and safety prior to human clinical trials is a crucial part of drug development, which deserves greater emphasis to reduce the cost and time in drug discovery. Recent advances in microfabrication and tissue engineering have given rise to organ-on-a-chip, an in vitro model capable of recapitulating human organ functions in vivo and providing insight into disease pathophysiology, which offers a potential alternative to animal models for more efficient pre-clinical screening of drug candidates. In this review, we first give a snapshot of general considerations for organ-on-a-chip device design. Then, we comprehensively review the recent advances in organ-on-a-chip for drug screening. Finally, we summarize some key challenges of the progress in this field and discuss future prospects of organ-on-a-chip development. Overall, this review highlights the new avenue that organ-on-a-chip opens for drug development, therapeutic innovation, and precision medicine.
